Highlights

  • Cynata Therapeutics Ltd (ASX:CYP) shares touched a fresh 52-week low on 24 August 2026.
  • The stock declined by 8.33 percent during the session.
  • Trading turnover for the day was comparatively light.
  • The one-year decline for the stock has been particularly steep.
  • Cynata Therapeutics is classified within the healthcare sector on the ASX.

Cynata Therapeutics Ltd, listed on the Australian Securities Exchange under the code CYP, recorded a new 52-week low during the Trading session on 24 August 2026. The company is categorised within the healthcare sector, which includes businesses engaged in biotechnology and therapeutic development.

Shares closed at $0.011, the lowest price point reached over the preceding twelve-month period. This kind of price marker is commonly referenced by Market Participants to describe a stock's recent trading range.

How the Stock Traded on the Day

The stock fell by $0.001 during the session, a decline of 8.33 percent from the previous close. At such a low absolute price level, even a single-cent movement can equate to a comparatively large percentage change.

Turnover for the day was recorded at approximately 2,696 shares, a relatively light figure that offers some indication of trading interest in the counter during the session.

A Longer-Term Perspective

Over the past twelve months, Cynata Therapeutics shares have declined by 94.21 percent, a particularly steep figure that places the day's move within the context of a substantial longer-term downward trend rather than an isolated single-session event.

The company's Market Capitalisation stood at $2.68 million at the time this data was recorded, placing Cynata Therapeutics among the smaller-capitalisation companies listed within the ASX healthcare and biotechnology space.

Healthcare and Biotechnology Sector Context

Biotechnology and therapeutics companies such as Cynata Therapeutics can see their share prices affected by factors including clinical trial progress, regulatory milestones, and the availability of funding to support ongoing Research and Development activities. These factors can shift considerably over time, contributing to periods of significant price movement within the sector.

As with any 52-week low, the figure itself is a technical marker of trading history rather than a complete explanation of a company's scientific or operational progress. Readers wishing to understand the fuller context are encouraged to review the company's official announcements and financial disclosures.

Why the Scale of the Yearly Decline Matters

The magnitude of Cynata Therapeutics' one-year change is considerably larger than what is typically seen among the companies covered in this series, underlining the importance of reviewing both the single-day move and the broader twelve-month trend together when following a stock of this kind.

As a smaller-capitalisation biotechnology company, Cynata Therapeutics' share price can be more sensitive to shifts in trading Volume than larger, more established healthcare companies on the exchange, which is a general pattern observed across smaller listed stocks rather than a specific comment on this company alone.

Conclusion

Cynata Therapeutics Ltd shares marked a new 52-week low during the 24 August 2026 session, extending a steep decline that has unfolded over the past twelve months. This article is based solely on the trading data available for the session and is intended for educational purposes only. Readers should refer to official company sources and exercise their own judgement when following the stock further.